Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

Robert J. Morgan,James H. Doroshow,Lucille Leong,Jeffrey Schriber,Stephen Shibata,S. Forman,Victor Hamasaki,Kim Margolin,George Somlo,Joseph Alvarnas,Mark McNamara,Jeffrey Longmate,James Raschko,Warren Chow,Steven A. Vasilev,Kathryn F. McGonigle,Yun Yen

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

2001

Robert J. Morgan
James H. Doroshow
Lucille Leong
Jeffrey Schriber
Stephen Shibata
S. Forman
Victor Hamasaki
Kim Margolin
George Somlo
Joseph Alvarnas
Mark McNamara
Jeffrey Longmate
James Raschko
Warren Chow
Steven A. Vasilev
Kathryn F. McGonigle
Yun Yen

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

Keywords:

Immunology
Ovarian cancer
Cancer
Etoposide
Stem cell
Doxorubicin
Chemotherapy
Nitrogen mustard
Cyclophosphamide
Medicine
Mucositis
Population

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations